Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04882124 · ClinicalTrials.gov registry record · Phase 2
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT04882124 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT04882124, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo. For this, the impact of CSJ117 on disease symptom burden and lung function will be explored.
Interventions
- DRUG Placebo
- DRUG CSJ117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-09-24 |
| Est. Completion | 2022-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04882124
The ClinicalTrials.gov registry entry for NCT04882124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04882124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04882124 about?
NCT04882124 is a clinical study titled "Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD". This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo. For this, the impact of CSJ117 on disease symptom burden and lung function wil...
What is the current status of trial NCT04882124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2021-09-24. Estimated completion is 2022-09-15.
What interventions are being tested in trial NCT04882124?
The interventions under investigation include: Placebo (DRUG), CSJ117 (DRUG).
Who is sponsoring clinical trial NCT04882124?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.